Back Other Health News Other Health News Topics Other STDs Herpes

Helicase Inhibitor Pritelivir Shows Promise Against Genital Herpes

Pritelivir, a helicase inhibitor that interferes with viral replication, reduced the rate of herpes simplex virus type 2 (HSV-2) genital shedding, which has the potential to reduce sexual transmission, according to a small study described in the January 16, 2014, New England Journal of Medicine.


Herpes Simplex and Cytomegalovirus Linked to Cognitive Impairment

Latent herpes simplex virus (HSV) or cytomegalovirus (CMV) infection may contribute to impaired cognitive processing for people of all age groups, possibly due to resulting inflammation, according to study results published in the November 18, 2013, advance edition of the Journal of Infectious Diseases.


IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression

Several studies presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last month in Rome showed that treating herpes simplex virus type 2 (HSV-2) with acyclovir or valacyclovir (Valtrex) reduced HIV viral load and slowed disease progression.


ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding

An experimental immune-modulating vaccine significantly reduced shedding of herpes simplex virus type 2 (HSV-2) in people with recurrent genital herpes, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The vaccine appeared safe and well-tolerated.


Genital Herpes Virus Can Spread Despite Lack of Symptoms

People without genital sores or other symptoms can still shed and transmit herpes simplex virus type 2 (HSV-2) during sex, according to a recent U.S. study. alt

Researchers Report Setbacks on Herpes Simplex Vaccine and Treatment

An experimental herpes simplex virus (HSV) vaccine partially protected women against infection with HSV type 1 but not type 2, according to a recent report in the New England Journal of Medicine. Another recent study found that antiviral treatment with acyclovir (Zovirax) or valacyclovir (Valtrex) did not prevent periodic HSV-2 reactivation and viral shedding.alt

Oral Tenofovir Does Not Reduce Herpes Virus Shedding

HIV positive people who took tenofovir (Viread, also in the Truvada and Atripla combination pills) as part of their antiretroviral regimen were no less likely to shed herpes simplex virus 1 or 2 (HSV-1 or HSV-2) than individuals using non-tenofovir regimens, according to research described in the January 14, 2011, issue of AIDS. These findings are notable because a recent microbicide study found that a tenofovir gel reduced the likelihood of HSV-2 infection.

Tenofovir Microbicide Gel May Prevent Genital Herpes in Addition to HIV Infection

A vaginal gel containing the HIV nucleotide reverse transcriptase inhibitor tenofovir (known as Viread in pill form, also in the Truvada and Atripla coformulations) inhibits replication of herpes simplex virus, researchers reported in the October 4, 2011, issue of Cell Host and Microbes. Tenofovir gel has already been shown to reduce HIV infection by about 40%, and the new findings suggest it may have a dual benefit.alt